[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Rule 144 notice discloses a proposed sale of 50,000 common shares through UBS Financial Services (Nasdaq) with an aggregate market value of $1,092,666 and an approximate sale date of 09/22/2025. The shares were acquired and paid for on 09/22/2025 via an equity option exercise from Surgery Partners, Inc. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling large share blocks between 08/21/2025 and 09/19/2025, including transactions of 100,000, 150,000, and other lots with combined gross proceeds in the multi-million dollar range. The filer affirms no undisclosed material adverse information.

Positive

• Filing complies with Rule 144 disclosure requirements including broker, acquisition details, and prior sales history
• Transaction transparency: acquisition method (equity option exercise) and payment date are explicitly stated

Negative

• Substantial insider selling documented: multiple large sales between 08/21/2025 and 09/19/2025, including blocks of 100,000 and 150,000 shares
• Concentrated disposals by one individual may be perceived negatively by investors and could increase selling pressure

Insights

Securities Analyst

Insider liquidity is high; recent large sales could increase supply pressure on the stock short term.

The filing shows a proposed sale of 50,000 shares following an equity option exercise and documents extensive open-market sales by Wayne DeVeydt across August and September 2025. The disclosed gross proceeds across multiple trades total several million dollars, indicating meaningful insider monetization rather than a single small disposition. From a market-impact perspective, clustered large insider sales can increase available float and may be perceived negatively by investors unless offset by clear company-positive developments. Compliance with Rule 144 is properly documented.

Corporate Governance Expert

Disclosure appears compliant; frequency and size of sales raise governance and signaling questions.

The notice complies with Rule 144 requirements by identifying the broker, the acquisition method (equity option exercise), and listing prior sales. However, the pattern of repeated, sizable sales by a single individual within a short period could prompt stakeholder questions about insider intent and board/insider communication. The filer’s attestation that no undisclosed material adverse information exists is noted, but governance teams typically monitor such concentrated dispositions for reputational and signaling effects.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	50000	1092666	128209410	09/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/22/2025	equity compensation	Surgery Partners, Inc.			50000	09/22/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	562150
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/04/2025	25000	562756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/05/2025	25000	563682
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/08/2025	2014	45207
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/11/2025	100000	2200741
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/12/2025	28700	628929
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/16/2025	25000	541518
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/17/2025	85785	1873875
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/18/2025	150000	3294425
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/19/2025	10613	234547

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for SGRY disclose about the proposed sale?

It discloses a proposed sale of 50,000 common shares through UBS Financial Services with an aggregate market value of $1,092,666 and an approximate sale date of 09/22/2025.

How were the 50,000 shares acquired according to the filing?

The shares were acquired on 09/22/2025 via an equity option exercise from Surgery Partners, Inc., with payment indicated as an equity option exercise on the same date.

Who has sold SGRY shares recently according to the filing?

Wayne DeVeydt is listed as the seller of multiple common stock transactions between 08/21/2025 and 09/19/2025 with several large lots and multi-million dollar gross proceeds.

Does the filer state any undisclosed material information in the Form 144?

The filer affirms they do not know any material adverse information regarding the issuer that has not been publicly disclosed.

Which broker is handling the proposed sale in the filing?

UBS Financial Services Inc., 1000 Harbor Blvd, Weehawken NJ is named as the broker for the proposed sale.